◆ NeutralIBRX

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc.·
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its Anktiva drug capabilities, causing investor losses when the truth was revealed.

Read Full Article at GlobeNewswire Inc.
← Back to Financial Intelligence